Rezolute

Rezolute will need to raise additional capital before mid-2027 unless it secures a near-term non-dilutive partnership or milestone payment, because existing cash is insufficient to fund operations through BLA submission. If true, management can execute clinical/regulatory milestones without crushing dilution; if false (i.e., they cannot raise funding), shareholders face severe dilution or failure-to-continue risks.

The failed sunRIZE primary SMBG endpoint leaves congenital HI approval uncertain; unless FDA accepts CGM-based endpoints and the totality of data, the congenital-HI indication will likely require additional data and will not contribute near-term value. If the FDA accepts the CGM signals and pharmacologic markers, congenital HI could broaden the label and commercial upside; if the Agency requires new randomized trials, development time, cost, and capital needs will increase materially.

Absent a non-dilutive financing or revenue, equity dilution is the likely outcome and will keep EPS negative; management’s reliance on capital markets means EPS_diluted will remain negative through approval absent a major change in funding strategy. Dilution reduces per-share upside from any approval; conversely, a partner or revenue would preserve more upside for existing shareholders.